|1.60|| +0.05 / +3.23%|
XTL Biopharmaceuticals Ltd engages in the acquisition and development of proprietary products and late-stage pharmaceutical products for the treatment of unmet clinical needs. It has three product candidates in clinical development: the hCDR1 peptide for the treatment of Systemic Lupus Erythematosus; Recombinant Erythropoitin for the prolongation of multiple myeloma advanced-stage patients' survival and improvement of their quality of life; and SAM-101, a therapy for psychotic diseases, with focus on schizophrenia. The company was founded on March 9, 1993 and is headquartered in Raanana, Israel.
|Joshua Levine||Chief Executive Officer|
|David Kestenbaum||Chief Financial Officer|
|Moshe Mittelman||Medical Director|
|Daniel H. Shapira||Internal Auditor|